Valeant Pharmaceuticals International (VRX)
$32.60
-0.68 (-2.04%)
| CAPS Rating |
|
|---|---|
| Open | $32.15 |
| Previous Close | $33.28 |
| Daily Range | $31.88 - $32.95 |
| 52-Week Range | $15.64 - $34.44 |
| Market Cap | $2.65B |
| P/E Ratio | 446.75 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,817,434 |
| Average Daily Volume | 772,000 |
VRX
VS S&P 500 (SPY)
How do you think VRX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
VRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
VRX News and Commentary
- Valeant may fall if new drug disappoints-Barron's – Reuters
- UPDATE 1-Valeant Q3 beats estimates, raises '09 profit view – Reuters
- BUY Valeant Pharma (VRX) – Blog at The Motley Fool
- Funds that are way up: Osterweis – CNN Money
- 3 Stocks Ready to Roar – The Motley Fool
- Stocks the Rich Executives Are Buying – The Motley Fool
- A Valeant Effort – The Motley Fool
- The 10 Hottest Stocks of 2008 – The Motley Fool
- The Best Small-Cap ETFs – The Motley Fool
- 3 Stocks Ready to Roar – The Motley Fool
- 5 More Top Growth Stocks – The Motley Fool
- Valeant's CEO has bought approximately 300,000 shares on the open market since May 30th.. – Blog at The Motley Fool
- Who's Buying Now? – The Motley Fool
- Thursday's Worst Stocks in the World – The Motley Fool
- Metabasis Gets Whacked – The Motley Fool
Related News and Articles
- The Side Effect of Developing Obesity Drugs – The Motley Fool
- How I'm Grabbing 20% Dividend Yields – The Motley Fool
- Are These Dividends Too Good to Be True? – The Motley Fool
RSS Headlines
Fool UK
